Across Europe , ACE-031, in its 1mg dose , is being evaluated as a novel option for a targeted disease area. Clinical trials in countries like Deutschland and Gallia are investigating its impact on clinical results . Regulatory bodies throughout the region are keeping a watch on the progress of A